EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin

Jing Qian, Wei Cheng, Shuangyan Li, Li Deng, Di Gao, Xue Zhang, Yunhui Zhang

Frontiers in Pharmacology · 14.01.2026 · 16

DOI: 10.3389/fphar.2025.1727729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.01.2026. Verfasst von Jing Qian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital,…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rhoifolin (ROF), a naturally occurring flavonoid, exhibits broad bioactivities, but its therapeutic potential and underlying mechanisms in lung cancer remain largely unknown. This study was designed to systematically investigate the anti-tumor effects of ROF and identify its key molecular targets. Materials and methods Anti-tumor activities of ROF were assessed using CCK-8, colony formation, flow cytometry, wound healing, and Transwell assays, respectively. An integrated approach combining network pharmacology, transcriptomic analysis with machine learning was employed to identify primary targets. The Kaplan-Meier survival and ROC curve analyses also evaluated the targets’ clinical outcomes and tumor microenvironment through the Cancer Genome Atlas (TCGA) data and single-cell RNA sequencing. The confirmed experimentally via RT-qPCR, Western blot, and immunofluorescence. The drug-target interaction was characterized by molecular docking and dynamics simulations. Finally, the in vivo antitumor efficacy and the safety of ROF were assessed in an H358 xenograft mouse model.

Results

ROF potently inhibited lung cancer cell proliferation (IC 50 : 15.35–33.84 µM), migration, and invasion, while inducing G 2 /M phase arrest and apoptosis (increased Bax/Bcl-2 ratio). ROF also impaired metastatic potential as evidenced by upregulated E-cadherin and downregulated N-cadherin in vitro . EPHB2 was identified as the most therapeutically relevant, showing high diagnostic value (AUC=0.856) and a significant correlation with poor patient survival. The experimental validation confirmed that ROF downregulates EPHB2 expression at both the mRNA and protein levels in a dose-dependent manner. Molecular docking and dynamics simulations predicted a stable, high-affinity interaction between ROF and the EPHB2 protein. Importantly, ROF treatment significantly suppressed tumor growth in vivo without discernible toxicity.

Conclusion

Rhoifolin exerts potent and selective anti-lung cancer activity by directly targeting and downregulating EPHB2, providing a strong rationale for its further development as a novel therapeutic agent for lung cancer.

Schlagwörter

Stichwörter der Autor:innen

EPHB2Rhoifolin (ROF)lung cancermolecular dynamics simulationsnetwork pharmacology

Autor:innen und Institutionen

  • Department of Respiratory Medicine, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital, Kunming, China.
  • Chongqing Key Laboratory of New Drug Screening from Traditional Chinese Medicine, Integrative Science Center of Germplasm Creation in Western China (Chongqing) Science City and Southwest University, SWU-TAAHC Medicinal…
  • Department of Oncology, 920th Hospital of the Joint Logistics Support Force of PLA, Kunming, China.
  • Department of Pathology, The First People's Hospital of Yunnan Province, Kunming University of Science and Technology Affiliated Hospital, Kunming, China.
  • College of Foreign Languages, Qingdao City University, Qingdao, China.

Zitieren

APA

Qian, J., Cheng, W., Li, S., Deng, L., Gao, D., Zhang, X., & Zhang, Y. (2026). Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1727729

Vancouver

Qian J, Cheng W, Li S, Deng L, Gao D, Zhang X, et al. Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1727729

BibTeX
@article{Qian2026,
  author = {Qian, Jing and Cheng, Wei and Li, Shuangyan and Deng, Li and Gao, Di and Zhang, Xue and Zhang, Yunhui},
  title = {Network pharmacology, bioinformatics and in vitro/in vivo validation elucidate the anti-lung cancer activities and potential targets of Rhoifolin},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fphar.2025.1727729}
}
Kostenlos starten →